PLoS ONE (Jan 2015)

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

  • Chantal E Hargreaves,
  • Chisako Iriyama,
  • Matthew J J Rose-Zerilli,
  • Sietse Q Nagelkerke,
  • Khiyam Hussain,
  • Rosalind Ganderton,
  • Charlotte Lee,
  • Lee R Machado,
  • Edward J Hollox,
  • Helen Parker,
  • Kate V Latham,
  • Taco W Kuijpers,
  • Kathleen N Potter,
  • Sarah E Coupland,
  • Andrew Davies,
  • Michael Stackpole,
  • Melanie Oates,
  • Andrew R Pettitt,
  • Martin J Glennie,
  • Mark S Cragg,
  • Jonathan C Strefford

DOI
https://doi.org/10.1371/journal.pone.0142379
Journal volume & issue
Vol. 10, no. 11
p. e0142379

Abstract

Read online

Cancer immunotherapy has been revolutionised by the use monoclonal antibodies (mAb) that function through their interaction with Fc gamma receptors (FcγRs). The low-affinity FcγR genes are highly homologous, map to a complex locus at 1p23 and harbour single nucleotide polymorphisms (SNPs) and copy number variation (CNV) that can impact on receptor function and response to therapeutic mAbs. This complexity can hinder accurate characterisation of the locus. We therefore evaluated and optimised a suite of assays for the genomic analysis of the FcγR locus amenable to peripheral blood mononuclear cells and formalin-fixed paraffin-embedded (FFPE) material that can be employed in a high-throughput manner. Assessment of TaqMan genotyping for FCGR2A-131H/R, FCGR3A-158F/V and FCGR2B-232I/T SNPs demonstrated the need for additional methods to discriminate genotypes for the FCGR3A-158F/V and FCGR2B-232I/T SNPs due to sequence homology and CNV in the region. A multiplex ligation-dependent probe amplification assay provided high quality SNP and CNV data in PBMC cases, but there was greater data variability in FFPE material in a manner that was predicted by the BIOMED-2 multiplex PCR protocol. In conclusion, we have evaluated a suite of assays for the genomic analysis of the FcγR locus that are scalable for application in large clinical trials of mAb therapy. These assays will ultimately help establish the importance of FcγR genetics in predicting response to antibody therapeutics.